Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01224769

Enrollment

109

Registered

2010-10-20

Start date

2005-09-30

Completion date

2009-12-31

Last updated

2010-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Brief summary

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Interventions

DRUGbendamustine +/- rituximab

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with relapsed or refractory chronic lymphoproliferative disorders * salvage treatment with bendamustine +/- rituximab * age ≥ 18 years

Exclusion criteria

* previous treatment with bendamustine

Design outcomes

Primary

Measure	Time frame
overall response rate	within 1 month after end of treatment

Secondary

Measure	Time frame
grade III and IV (NCI Common Toxicity Criteria) adverse events	within 1 month after end of treatment
prognostic factors	within 1 month after end of treatment
progression free survival	within 1 month after end of treatment
overall survival	within 1 month after end of treatment

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026